Glenmark

Glenmark to conduct trials for potential COVID-19 drug, first company in India to receive DCGI approval; shares jump 9%

Glenmark filed the product for clinical trials with the DCGI and has received approval for conducting the trial on mild to moderate patients, said the BSE filing.

Glenmark Pharmaceuticals gets USFDA's final nod for Deferasirox tablets; company shares trade higher

The tablet is used to treat high levels of iron in the body caused by multiple blood transfusions

Q2 results paint a bleak picture for market, Adani Ports and SEZ in stable waters; all this and more on Moneycontrol Pro

Adani Ports volumes rose sharply despite depressed market conditions in global trade, which has affected India’s trade too.

How should Reserve Bank manage the rupee, stock picks from tech analysts; all this and more on Moneycontrol Pro

As the economic slowdown depeens, different government officials are speaking in different voices

India pharma majors Dr Reddy's, Wockhardt, and others deny allegations of conspiracy to fix prices in US

The generic drug makers are named in an anti-trust lawsuit in the US on allegations of engaging in a conspiracy to fix prices

Glenmark gets USFDA nod for generic blood pressure medicine

Shares of Glenmark Pharmaceuticals were trading 2.17 percent up at Rs 625.20 on BSE

Delhi HC sets aside Centre's ban on 344 fixed dose combination medicines

Defending its stand, the Centre had argued that the FDC medicines are "new drugs" and thus, require licence from Drugs Controller General for sale and manufacture.

FIPB clears 11 FDI proposals, refers Glenmark, Aurobindo deals to CCEA

FIPB has cleared foreign invest in 11 entities, worth Rs 1,075.91 cr, referred proposals worth Rs 4,187 crore in firms - Glenmark and Aurobindo - to CCEA

Delhi HC allows Glenmark to make, sell antibiotic drug Linezolid

Delhi High Court today set aside its single judge's order restraining Mumbai-based generic drug maker Glenmark Pharmaceuticals Ltd from making and selling its antibiotic medicine Linezolid.

Starmine data predicts Glenmark profit may miss estimates

Glenmark Pharmaceuticals could miss January-March earnings consensus forecast, according to Thomson Reuters StarMine data.